GPR162 and Alzheimer disease: An integrative model combining age, the ratio of GABRD+-carrying pTau217 EVs and GPR162+-carrying pTau217 EVs, the corresponding size of distribution mode of GABRD+-carrying pTau217 EVs and GPR162+-carrying pTau217 EVs effectively discriminated AD from HC with an AUC of 0.93 (95% CI 0.879–0.977; sensitivity = 91.67%, specificity = 82.61%) (Fig. 5i) and distinguish AD from NAD with an AUC of 0.90 (95% CI 0.815–0.965; sensitivity = 89.58%, specificity = 75.86% (Fig. 5j).